REQUIRED for HF Accreditation: NYHA/symptoms with activity performed?
Indicate whether documented NYHA classification
has been completed or documented symptoms with activity, this can be documented by nursing staff or physician.
Class I: patients with cardiac disease but without resulting limitations of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea.
Class II: patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, or dyspnea.
Class III: patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea.
Class IV: patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms are present even at rest or minimal exertion.
HAS-BLED is a risk score designed to predict the one year risk for major bleeding in AF patients and may be used to aid in clinical decision making regarding anticoagulation therapy. HAS-BLED is an acronym for the bleeding risk factors that are assessed: Hypertension (uncontrolled, > 160 mm Hg systolic), Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly (age >65 years), and Drugs/alcohol concomitantly (antiplatelet agents, non-steroidal anti-inflammatory drugs). A high HAS-BLED score is associated with a high risk of hemorrhage. When used in conjunction with a stroke risk score, HAS-BLED may be able to help one weigh the stroke risk and bleeding risk to determine the best course of action for anticoagulation therapy. It is important to note however, that CHADS2 and CHADS2-VASc stroke risk scores contain some of the same risk factors as HAS-BLED. The results of the HAS-BLED score should be interpreted with this in mind.
This is my second time using this particular Lab. I've previous positive experience with Sis (when formerly known as Infiniti Labs) Anavar, so my expectations were some what inflated:)
Firstly, I was really impressed by the immaculate packaging of this product, which shows how much effort went into its manufacturing and marketing. I ran this product at a weekly dose of 400mg, in conjunction with Mast e and Test. Prior to introducing Sis Tren e into my current cycle, I was already using a different Labs Tren at a slightly higher dose of 500mg weekly. To be honest, I did not notice any difference, even when running Sis Tren e at a slightly lowered dose of 400mg for 5 weeks in total. I continued with making strength gains with a noticeable reduction in body fat, even though my diet wasn't always on point. I have had no adverse effects from the Tren, unless if you want to include night sweats. Overall, I am very satisfied with the results I got from use of this product.